Last reviewed · How we verify
Piloting Pathways With Lung Cancer Patients
NA trial testing Pathways in Metastatic Lung Cancer in 53 participants. Completed in 3 August 2022.
| Lead sponsor | Laurie McLouth |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 53 |
| Start date | 13 January 2020 |
| Primary completion | 3 August 2022 |
| Estimated completion | 3 August 2022 |
| Sites | 1 location across United States |
Laurie McLouth
18 and older, any sex, with Metastatic Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of eligible and approached patients who agree to participate
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 53 |
Mean acceptability ratings on individual items of acceptability developed by study team (e.g., convenience of the intervention, helpfulness of the intervention, relevance of the intervention; scores of at least 7/10 on each item, possible range = 1-10, higher scores indicate higher acceptability).
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 8.79 | ± 1.17 |
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 8.46 | ± 1.67 |
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 8.54 | ± 1.55 |
Brief measure of satisfaction with ability and participation in activities and roles (e.g., work at home, regular personal and household responsibilities, do things for family) Higher scores indicate more satisfaction with participation. Raw scores range from 8 to 40. 8 items are responded to on a scale of 1 = not at all to 5 = very much.
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 21.8 | ± 9.54 |
Brief measure of agency and pathways thinking. 6 items responded to on a scale of 1 = definitely false to 8 = definitely true. Items are summed for a total score (possible range = 6 - 48). Higher scores indicate higher hope.
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 31.3 | ± 7.9 |
Brief measure assessing one's sense of purpose and that there are reasons for living; 4 items responded to on a scale of 1 = not at all to 5 = very much (possible raw score range = 4 - 20). Higher scores indicate greater meaning and purpose.
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 16.4 | ± 3.7 |
Brief measure assessing sense of worthlessness, helplessness, depression, etc. 6 items are responded to on a scale of 1 = never to 5 = always (possible raw scores range from 6-30). Higher scores indicate greater distress.
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 11.3 | ± 5.87 |
measure of lung cancer stigma. 25 items making up three subscales (perceived stigma, internalized stigma, and constrained disclosure). Items are responded to on a scale of 1 = not at all to 5 = extremely. Items are summed, with a higher score indicating greater lung cancer stigma/worse outcome (possible total score range = 25-125) . Clinical cutoff of a total score of 37.5 is suggested in literature as significant levels of stigma.
| Group | Value | 95% CI |
|---|---|---|
| Pathways | 52 | ± 15.7 |
The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.
2 peer-reviewed publications reference this trial (live from Europe PMC):
Verify or expand the search:
Trials testing the same drug.
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04161157.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing